569 related articles for article (PubMed ID: 27984714)
1. IL-17 Blockade in Psoriasis.
Burkett PR; Kuchroo VK
Cell; 2016 Dec; 167(7):1669. PubMed ID: 27984714
[TBL] [Abstract][Full Text] [Related]
2. IL-17 for therapy.
Kurschus FC; Moos S
J Dermatol Sci; 2017 Sep; 87(3):221-227. PubMed ID: 28633806
[TBL] [Abstract][Full Text] [Related]
3. IL-17 inhibitors for psoriasis.
Paek SY; Frieder J; Kivelevitch D; Menter MA
Semin Cutan Med Surg; 2018 Sep; 37(3):148-157. PubMed ID: 30215631
[TBL] [Abstract][Full Text] [Related]
4. Anti-IL-17 Medications Used in the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review.
Canavan TN; Elmets CA; Cantrell WL; Evans JM; Elewski BE
Am J Clin Dermatol; 2016 Feb; 17(1):33-47. PubMed ID: 26649440
[TBL] [Abstract][Full Text] [Related]
5. Effect of IL-17A blockade with secukinumab in autoimmune diseases.
Patel DD; Lee DM; Kolbinger F; Antoni C
Ann Rheum Dis; 2013 Apr; 72 Suppl 2():ii116-23. PubMed ID: 23253932
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-17 (IL-17) inhibitors in the treatment of plaque psoriasis: a review.
Gooderham M; Posso-De Los Rios CJ; Rubio-Gomez GA; Papp K
Skin Therapy Lett; 2015; 20(1):1-5. PubMed ID: 25807214
[TBL] [Abstract][Full Text] [Related]
7. Anti-interleukin-17 treatment of psoriasis.
Jinna S; Strober B
J Dermatolog Treat; 2016 Aug; 27(4):311-5. PubMed ID: 26943806
[TBL] [Abstract][Full Text] [Related]
8. The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis.
AbuHilal M; Walsh S; Shear N
J Cutan Med Surg; 2016 Nov; 20(6):509-516. PubMed ID: 27207350
[TBL] [Abstract][Full Text] [Related]
9. IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis.
Krueger JG; Wharton KA; Schlitt T; Suprun M; Torene RI; Jiang X; Wang CQ; Fuentes-Duculan J; Hartmann N; Peters T; Koroleva I; Hillenbrand R; Letzkus M; Yu X; Li Y; Glueck A; Hasselberg A; Flannery B; Suárez-Fariñas M; Hueber W
J Allergy Clin Immunol; 2019 Sep; 144(3):750-763. PubMed ID: 31129129
[TBL] [Abstract][Full Text] [Related]
10. Treating to Target(s) With Interleukin-17 Inhibitors.
Lynde CW; Beecker J; Dutz J; Flanagan C; Guenther LC; Gulliver W; Papp K; Rahman P; Sholter D; Searles GE
J Cutan Med Surg; 2019; 23(2_suppl):3S-34S. PubMed ID: 30742778
[TBL] [Abstract][Full Text] [Related]
11. No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis.
Bokor-Billmann T; Schäkel K
J Dermatolog Treat; 2019 May; 30(3):216-220. PubMed ID: 30051725
[TBL] [Abstract][Full Text] [Related]
12. The advent of IL-17A blockade in ankylosing spondylitis: secukinumab, ixekizumab and beyond.
Dubash S; Bridgewood C; McGonagle D; Marzo-Ortega H
Expert Rev Clin Immunol; 2019 Feb; 15(2):123-134. PubMed ID: 30576610
[TBL] [Abstract][Full Text] [Related]
13. Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F.
Adams R; Maroof A; Baker T; Lawson ADG; Oliver R; Paveley R; Rapecki S; Shaw S; Vajjah P; West S; Griffiths M
Front Immunol; 2020; 11():1894. PubMed ID: 32973785
[TBL] [Abstract][Full Text] [Related]
14. Secukinumab for children and adolescents with enthesitis-related arthritis and psoriatic arthritis:
Bagri NK; King H; Ramanan AV
Expert Rev Clin Immunol; 2024 May; 20(5):435-440. PubMed ID: 38186357
[TBL] [Abstract][Full Text] [Related]
15. Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.
Vu TT; Gooderham M; Papp K
Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1423-1433. PubMed ID: 27690669
[TBL] [Abstract][Full Text] [Related]
16. Ixekizumab: a new anti-IL-17A monoclonal antibody therapy for moderate-to severe plaque psoriasis.
Blauvelt A
Expert Opin Biol Ther; 2016; 16(2):255-63. PubMed ID: 26666707
[TBL] [Abstract][Full Text] [Related]
17. Secukinumab: first global approval.
Sanford M; McKeage K
Drugs; 2015 Feb; 75(3):329-38. PubMed ID: 25648267
[TBL] [Abstract][Full Text] [Related]
18. Pathogenic role of IL-17 in psoriasis and psoriatic arthritis.
Chiricozzi A
Actas Dermosifiliogr; 2014 Oct; 105 Suppl 1():9-20. PubMed ID: 25398488
[TBL] [Abstract][Full Text] [Related]
19. Secukinumab (AIN-457) for the treatment of Psoriasis.
Jaleel T; Elmets C; Weinkle A; Kassira S; Elewski B
Expert Rev Clin Pharmacol; 2016; 9(2):187-202. PubMed ID: 26647300
[TBL] [Abstract][Full Text] [Related]
20. Anti-IL17 therapies for psoriasis.
Silfvast-Kaiser A; Paek SY; Menter A
Expert Opin Biol Ther; 2019 Jan; 19(1):45-54. PubMed ID: 30500317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
